Quantifying Preferences for CAR‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma

Quantifying Preferences for CAR‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma

ABSTRACT Background CAR‐T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early‐line MM raises questions on the acceptability of upfront risks in exchange for extended relapse‐free pe...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessie Sutphin, Thomas W. LeBlanc, Ellen Janssen, Laura Hester, Matthew J. Wallace, F. Reed Johnson, Shelby D. Reed
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Medicine
Subjects:
benefit–risk
CAR‐T
discrete‐choice experiment
multiple myeloma
patient preferences
Online Access:https://doi.org/10.1002/cam4.71072
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71072

Similar Items